Gastrointestinal Cancers
Web Exclusives | November 16, 2021
Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.
Web Exclusives | November 16, 2021
Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer.
Web Exclusives | November 16, 2021
Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement.
Web Exclusives | November 16, 2021
Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer.
Web Exclusives | October 25, 2021
CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.
Web Exclusives | October 25, 2021
Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.
Web Exclusives | October 25, 2021
An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.
Web Exclusives | October 25, 2021
Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.
Web Exclusives | October 25, 2021
A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers.
Web Exclusives | October 25, 2021
Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512